Dianthus Therapeutics, Inc. (DNTH) Stock Ticker
DNTH right now
Market factors today
Unlock the full DNTH picture
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
DNTH stock facts
| Ticker symbol | DNTH |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $5.0B |
| CEO | Marino Garcia |
| Employees | 92 |
| Headquarters | New York, NY, US |
| IPO date | 2018-06-21 |
| Website | dianthustx.com |
What you can see for DNTH on Tickr
Live DNTH price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the DNTH report.
Rankings
FAQ
What is the ticker symbol for Dianthus Therapeutics, Inc.?
The ticker symbol for Dianthus Therapeutics, Inc. is DNTH, listed on the NASDAQ.
What is DNTH?
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that…